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The immune response to infectious organisms is 
dependent on the recognition of the products of  
'foreign' genes expressed within host cells. The con- 
cept of immunization therefore arises as a natural conse- 
quence of  gene transfer in mammals, and using 
recombinant molecular-genetic approaches to modu- 
late immune function represents a promising avenue 
of investigation for the prevention and treatment of  
cancer and infectious diseases. Immune recognition 
depends on the effective synthesis of  foreign gene 
products, together with appropriate presentation of 
these proteins to the immune system by the major 
histocompatibility complex (MHC). 
During the past few decades, the molecular and 
genetic bases of immune recognition have been eluci- 
dated. The roles of  the histocompatibility complex 
glycoproteins and the antigen-recognition structures, 
including antibody molecules and the T-cell receptor, 
have been defined at the molecular level. Through 
such studies, it has become evident that these 
immunological recognition structures have evolved to 
identify foreign proteins that are synthesized within 
cells, and to present them in a manner that permits 
immunological recognition and response. 
In addition to these advances in understanding the 
genetic basis of  immune recognition, considerable 
progress has been made in developing recombinant 
gene-transfer techniques in vivo. In nature, transfer of 
foreign genetic material by viruses and microorgan- 
isms often elicits effective immune responses, and suc- 
cessful vaccinations based on the deliberate introduc- 
tion of foreign vectors are well-documented. 
Attenuated virus vaccines, beginning with the use 
of the cowpox virus by Jenner to protect against small- 
pox infection, Pasteur's rabies vaccine, and numerous 
subsequent attenuated virus vaccines including polio, 
rubella, measles, mumps and yellow fever, represent 
widely tested and effective treatments in modern 
medicine. These approaches to immunization involve 
direct in vivo delivery and expression of  genes, i.e. 
genetic immunization in its most primitive form. In 
addition, these studies have documented the efficacy 
and potential therapeutic benefits that can be derived 
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when foreign genetic material is introduced directly 
into humans in vivo to prevent infection by specific 
pathogens. 
With the advent of  molecular genetics and the 
more-recent advances in gene-transfer techniques, it 
has become apparent that gene-transfer approaches can 
now be used efficiently and safely to address clinical 
problems of major medical significance. In particular, 
gene-transfer methods can be used to stimulate the 
immune system to recognize viruses, parasite-infected 
cells and cancerous cells. Such approaches could 
potentially be used to address major threats to public 
health, such as those posed by acquired immuno- 
deficiency syndrome (AIDS), tuberculosis and Lyme 
disease. In this review, the potential application 
of direct gene transfer to immunotherapy and 
immunization for treating diseases such as viral 
infections and cancer is discussed. 
Emergence of gene-delivery technology 
Efforts to identify methods for enhancing the 
delivery of functional polynucleotides into living cells 
were stimulated in the mid 1950s by the results of 
Alexander et al. (reviewed in 1Kef. 1), which demon- 
strated that purified poliovirus IKNA was infectious in 
HeLa cells. Although the infectivity of  the purified 
genomJc 1KNA was extremely low when compared 
with the original intact virus (up to one million times 
less active), this nevertheless showed that living virus 
particles were not required to produce competent, 
infectious virus in vivo. Moreover, the investigators 
showed that a hypertonic saline solution (]M NaC1) 
could enhance infectivity of the purified 1KNA by 
~100-fold. These humble beginnings led to improved 
methods for cellular transfection, including calcium 
phosphate co-precipitation 2 and diethyl aminoethyl 
(DEAE)-dextran 3. Subsequent experiments using the 
calcium-phosphate procedure demonstrated that 
transfection of  a non-infectious fragment of the her- 
pes simplex virus (HSV) genome containing the 
thymidine kinase (TK) gene could transform TK 
cells 4, i.e. an infectious and proliferating virus was 
unnecessary for cellular transformation. Transfection 
technology converged with the emerging recombi- 
nant DNA technology in the late 1970s when Berg 
and colleagues used calcium-phosphate, DEAE- 
dextran and liposomal transfection methods to deliver 
and express recombinant plasmids in cultured mam- 
malian cells s,6. 
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Effective non-viral delivery methods 
The efficiency with which intact viruses introduce 
genes into cultured cells led to the search to identify 
synthetic systems that could emulate viral delivery 
while avoiding viral infectivity 1,6,7. The two intrinsic 
viral attributes that have attracted the most attention 
in this regard are the specific interaction with cell- 
surface receptors on target cells, and viral membrane- 
fusion proteins. Receptors enable infectious particles 
to attach specifically to the surface of  target cells, 
whereas fusion proteins enable delivery of  the viral 
genome into the cytoplasm of  the host cell following 
receptor-mediated endocytosis. Viruses lacking a 
membrane-fusion capabili W would be trapped in the 
lysosomal pathway of  the cell and would be degraded 
by hydrolytic and oxidizing enzymes located in the 
lysosomes. In principle, fusion events leading to func- 
tional polynucleotide delivery can occur within the 
phagocytic vesicle compartment (phagosome), within 
the lysosomal compartment, or directly with the cell- 
surface plasma membrane. However,  two major tech- 
nical hurdles have prevented the widespread appli- 
cation of  conventional liposomes as vehicles for gene 
delivery. (1) The efficiency of  DNA encapsulation 
into conventional liposomes is usually very low 
because the internal volume of the vesicle is too small 
to encapsulate macromolecules the size of  genes 
efficiently and conveniently. (2) The transfection 
efficiency ofliposomal D N A  is also very low because 
the efficiency with which liposomes bypass the lyso- 
somal pathway is still too low. Liposomes that contain 
receptors that are capable of  interacting with specific 
target cells have been prepared and tested; they are 
capable of bypassing the lysosomal compartment by a 
protein-mediated or pH-sensitive fusion mechanism. 
Two additional gene-transfer approaches which do 
not use viral vectors, and which can also overcome 
some of  the problems encountered with conventional 
liposomes, are direct intramuscular injection of  
genetic material into tissue, and in vivo lipofection 
using cationic lipid-1)NA complexes. 
Polycationic delivery systems 
The commercially available cationic-lipid vector, 
Lipofectin 8,9, is one member of  a class of  cationic-lipid 
formulations called 'cytofectins' that can overcome 
many of  the problems associated with the use of con- 
ventional liposomes as gene-delivery vehicles. Cyto- 
fectin formulations consist of  cationic liposomes which 
have three properties that are of  particular importance 
to the delivery ofpolynucleotides. 
• These liposomes condense with DNA to form com- 
plexes in which all the DNA is entrapped, regardless 
of  its size. 
• Virtually all biological surfaces, including cell 
surfaces, carry a net negative charge. Thus, positively- 
charged lipid vesicles containing gene sequences inter- 
act spontaneously with cell surfaces, delivering the 
associated polynucleotide to the cell. 
• Cationic lipid-polynucleotide complexes fuse with 
cell membranes in a manner that allows the entrapped 
D N A  to avoid degradation in the lysosomal compart- 
ment. 
Although receptor-mediated phagocytosis usually 
enables even conventional liposomes to enter cells in 
reasonable amounts, these particles do not easily escape 
the lysosomal compartment of  the cell, which com- 
pletely degrades the liposomes and the encapsulated 
DNA. The cytofectin-mediated fusion, which leads to 
escape from lysosomal degradation, depends on the 
structure of  the cationic lipid molecule, as well as on 
the presence of  neutral lipids in the final formulation. 
Another notable polynucleotide-delivery system 
involving the use of  polycations is the polylysine- 
ligand conjugate system of  W u  1° and Birnstie111 . This 
system employs specific ligands, conjugated to polyly- 
sine, that spontaneously condense with DNA through 
disassociable ionic interactions. The resulting con- 
densate is taken up by receptor-mediated endocytosis 
into cells containing the receptor for the conjugated 
ligand. The addition of  chloroquine or adenovirus 
coat proteins can be used to disrupt the lysosomal 
compartment and release DNA into the cell. 
Exploiting viral sequences for in vivo gene 
delivery 
The use of  viruses as gene-transfer vehicles arose 
from the observation that viruses are extremely 
efficient at introducing genes into their host cells, and 
that they might therefore be useful as vectors for 
introducing genes to correct genetic diseases in man. 
In particular, since DNA and R N A  tumor viruses 
integrate into mammalian genomes, thus propagating 
the introduced genes on cell division, it was proposed 
that, if the deleterious features of these viruses could 
be eliminated, they might be able to deliver safely a 
desirable gene to correct the cellular defects of  genetic 
disorders12,13. Substantial progress has been made, in 
the past decade, towards the production of  safe and 
effective retroviral vectors but, until recently, inject- 
ing such vectors has been considered only for use in 
ex vivo protocols, not for direct in vivo gene transfer. 
Subsequently, it was found that it might be 
possible to exploit features of  viral sequences in 
improving infectivity of  introduced plasmid DNA, 
without the need for including infectious viruses. 
Among the earliest reported direct in vivo transfections 
using cloned genes without the use of  infectious virus 
vectors were experiments showing that virus repli- 
cation could occur following injection of  cloned 
infectious viral plasmid DNA in vivo (reviewed in P,.ef. 
14). The plasmid DNA used for these studies was puri- 
fied from bacteria and therefore did not contain any 
viral particles or proteins to facilitate uptake into the 
cell. These experiments contributed to a better under- 
standing of  the role of  specific viral genes in in vivo 
virus replication and oncogenesis, although at the 
time, little attention was paid to the possibili W of  using 
the apparent low level of  expression for therapeutic 
benefit. 
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Direct in vivo,  non-viral gene delivery 
Several different approaches have been used to 
introduce and obtain expression from non-replicating 
plasmid sequences in vivo. In addition to the use of  
techniques (e.g. liposomes, calcium phosphate pre- 
cipitates and polylysine conjugates) mentioned earlier, 
successful gene expression following direct injection 
of  'naked' nucleic acids and cationic-lipid-mediated 
delivery have been reported. 
Direct injection 
In a systematic survey to identify tissues permissive 
for in vivo delivery, we found that, in skeletal muscle, 
no cationic-lipid vector was necessary to achieve sig- 
nificant levels of  transgene expression 15. Up to one 
nanogram ofreporter-gene product [luciferase, chlor- 
amphenicol acetyltransferase (CAT) or [3-galacto- 
sidase] could be isolated from skeletal muscle injected 
in vivo with 10-100 mg ofplasmid DNA. Although 
there was no evidence of  integration into the host 
genome, expression persisted for more than six 
months. (Integration was not expected in the fully dif- 
ferentiated non-dividing muscle fibers in which the 
expression was detected, since integration requires cell 
division.) Persistent expression implied that the intro- 
duced sequences were maintained and repaired in the 
nucleus like genomic DNA. In vitro transcribed 
m R N A  was also taken up and expressed in mouse 
muscle, but the duration of  expression was much 
shorter. Several reports have subsequently demon- 
strated similar results with direct gene delivery in rat 
cardiac muscle u'. Directly injected recombinant DNA 
was expressed by a small percentage of  cardiac 
myocytes in the area of  injection, and the genes intro- 
duced in this way are regulated normally by hormonal 
signals. Another form of  direct gene delivery, other 
than direct injection, that has been used to introduce 
functional genes into living mammalian tissue is high 
energy microparticle bombardment 17. This approach 
has been used successfully to generate immune 
responses in vivo (see below). 
Cationic lipid-DNA complexes 
A number of  studies have shown that cationic- 
lipid-mediated reporter-gene transfer can mediate 
effective gene delivery in vivo, either by inj ection (into 
neural or lung tissue) 14, or by direct administration 
into the lung by aerosol or intubation 18 20. 
A catheter-based gene-delivery system has now 
also been used to localize the expression of  recom- 
binant genes to the anatomical site of  introduction. 
Plasmids can be transferred by lipofection into the 
arterial wall using a double-balloon catheter which 
isolates a space between the two balloons. Expression 
of different recombinant genes has been docu- 
mented 2>2s in porcine endothelial, vascular smooth 
muscle, and adventitial cells. Similar results have been 
reported in other species 2<2v. The arterial or venous 
circulation can also be used as a conduit to introduce 
genes into organs, or to sites of  focal pathology, for 
example, in tumor nodules (see below). 
Direct  gene transfer and m o d u l a t i o n  o f  the 
i m m u n e  system 
Immunotherapy 
Early studies used catheter-based gene delivery as 
a model system to demonstrate that specific reporter 
genes could be expressed in vivo 21,22. Subsequent 
studies investigated whether specific biological 
responses (i.e. immune responses) could be induced at 
sites of  recombinant gene transfer. A highly immuno- 
genie foreign M H C  molecule was used to elicit an 
immune response in the pig iliof~moral artery. Using 
direct gene transfer (either a retroviral vector or 
DNA-liposome complex24), the human HLA-B7 
gene was introduced into the artery and its expression 
was detected at specific sites within the vessel wall. 
More importantly, expression of  this foreign MH C 
antigen induced an immunological response at the sites 
of  genetic modification. (The response included a 
granulomatous mononuclear cell infiltrate beginning 
ten days after introduction of  the recombinant gene. 
This response resolved by 75 days after gene transfer; 
however, a specific cytolytic T-cell response against 
the HLA-B7 molecule was persistent.) Not  only was 
a specific immunological response induced by the 
introduction of  a recombinant gene at a specific site 
in vivo, but also this study showed that direct gene 
transfer of  specific recombinant genes could elicit an 
immune response to the product of  that gene in vivo 24. 
In addition, this approach provided a general method 
for the induction of  an immune response at a specific 
site in vivo. 
To determine whether direct gene transfer might 
be appropriate for the treatment of  disease, a murine 
model of  malignancy has been developed. Direct gene 
transfer of  an allogeneic (i.e. of  different genetic ori- 
gin) M H C  gene into a murine tumor elicits a T-cell- 
dependent immune response, not only to the foreign 
M H C  gene, but also to previously unrecognized 
tumor-associated antigens, which are now recognized 
within the context of  the 'self' MHC.  Thus, the 
immune system acquires the ability to recognize and 
lyse tumor cells which had previously evaded detec- 
tion. 
In animals presensitized to a specific M H C  haplo- 
type, direct gene transfer into established tumors could 
attenuate tumor growth or, in some cases, lead to 
complete tumor regression 2s. Direct gene transfer of  
foreign M H C  genes into tumors thus has potential 
therapeutic effects that may be appropriate for the 
treatment of  malignancy. 
As an extension of  this work, a clinical trial based 
on direct gene transfer received approval of  the 
Recombinant DNA Advisory Committee (RAC) of  
the National Institutes of  Health (NIH) on t0 
January, 1992. This clinical trial involved the treat- 
ment of  subcutaneous lesions of  patients with meta- 
static melanoma. The treatment consists of  intra- 
tumoral injection of  the human class 1 M H C  gene, 
HLA-B7, complexed to a cationic liposome Dope/  
3[3 [N', N'-dimethylaminoethane-carbamoyl] choles- 
terol 29,3° in escalating doses. Toxicity, expression of  
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the recombinant gene, and the immunological 
response to treatment are currently being evaluated. 
The objectives of  this first human clinical trial using 
direct gene transfer are: (1) to establish a safe and 
effective dose of  DNA-liposome complex to intro- 
duce recombinant genes in vivo; (2) to confirm ex- 
pression of  the transduced gene; and (3) to analyse the 
immune response and potential therapeutic effects of  
this method of  therapy. Toxicity has not readily been 
apparent in both long-term and short-term animal 
studies using these modes of  direct gene transfer in 
pip029,31,32. Taken together, these studies will deter- 
mine whether direct gene transfer is an appropriate 
form of  treatment for malignancy, and whether this 
method of  delivery might also be appropriate for treat- 
ing other human diseases. 
Immunization 
Two different pathways of  antigen processing lead 
to antigen presentation: either through M H C  class I 
or M H C  class II molecules 33. Extracellular antigens are 
taken up endocytically and the protease-digested frag- 
ments are presented by the M H C  class II molecules. 
This stimulates CD4 + helper T cells and amplifies the 
humoral immune response. Intracellular antigen syn- 
thesis leads to presentation by M H C  class I molecules 
and stimulation of  CD8 + cytotoxic T cells (CTLs). 
The ability to introduce foreign genes which can be 
expressed (i.e. intracellular antigen synthesis) enables 
the M H C  class I pathway to be preferentially stimu- 
lated and specific CD8 + cytotoxic T-cell responses to 
be increased. 
Humoral responses are involved in the neutraliz- 
ation of  active pathogens, whereas cellular CTL 
responses eliminate infected cells that are the source of  
the pathogens. Tbe live, attenuated virus vaccines in 
current use activate both the cellular and humoral arms 
of  the immune system, yielding a balanced response; 
this class of  vaccines is generally more effective, more 
cross-reactive and gives effects of  a longer duration 
than the responses induced by inactivated vaccines. 
The cross-reactivity of  the vaccine is particularly 
important for viruses such as influenza and human 
immunodeficiency vires (HIV) that undergo progress- 
ive antigenic drift. 
We undertook studies to determine whether direct 
administration ofplasmids encoding viral antigens that 
are subsequently expressed in muscle tissue could pro- 
duce a balanced immune response, similar to that associ- 
ated with attenuated virus vaccines 34. Balb/c mice 
were treated with a single 50 ILl intramuscular injec- 
tion of  100 btg of  a plasmid containing the gene for a 
secreted form of  the HIV gpl20 protein and 
driven by the CMV immediate-early promoter. High 
titer lgG antibodies directed against the gp 120 protein 
were produced and maintained for >6 months. The 
same injection procedure also induced potent, long- 
lasting and specific CTL responses against the gp120 
CTL peptide epitope. 
To  assess more thoroughly the quality of  the 
immune responses generated following injection of  
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plasmids encoding viral antigens, we used the mouse 
influenza model to carry out antiviral efficacy stud- 
ies 35,36. Plasmid cDNA encoding nucleoprotein (from 
the Puerto Rico strain of  influenza virus) injected into 
the quadriceps muscle of  Balb/c mice produced potent 
antibody and CTL responses against nucleoprotein. 
The results of  the quantitative immunological assays 
demonstrated that a single injection of  nucleoprotein 
DNA generated the appropriate nucleoprotein-derived 
peptide in association with M H C  class I antigen, for 
induction of  the specific CTL response. These CTLs 
could recognize the nucleoprotein peptide epitope 
generated on naturally infected cells. 
The in vivo protective efficacy of  the nucleo- 
protein-DNA immunization was demonstrated in sev- 
eral ways. Following challenge with live influenza 
virus, the nucleoprotein-DNA vaccinated mice had 
much lower influenza virus titers in their lungs, less 
weight loss due to infection, and greater survival from 
a lethal virus challenge than control-vaccinated animals. 
Thus, the use of  an expression vector encoding a viral 
protein as an immunogen offers a simple means to 
induce cross-strain protective immunity, without the 
need for live attenuated virus adjuvants or viral gene- 
transfer vectors. 
Future directions 
Judging from the magnitude and quality of data 
generated during the last three years, the prospects for 
direct in vivo gene delivery are very promising. Cyto- 
fectin formulations have been shown to facilitate 
delivery and gene expression in skin, brain and liver 
via direct injection into the tissue. In addition, other 
vectors, including polylysine-ligand complexes and 
viruses, have yielded expression following gene trans- 
fer in vivo. Expression of  specific recombinant genes 
in these tissues provides a potent method to induce 
immune reactivity against a variety of  gene products. 
After direct intramuscular injection, recombinant viral 
genes have induced immune responses which provide 
protective immunity against live virus infections, 
paving the way towards a new class of  more effective 
vaccines. Finally, direct gene transfer has been suc- 
cessful in providing immunotherapeutic responses in 
murine models of  malignancy. Based on these studies, 
a clinical protocol has been initiated to analyse the 
potential toxicity and efficacy of  this mode of  treat- 
ment in humans. If this form of  treatment is well- 
tolerated, direct gene transfer could simplify and facili- 
tate molecular-genetic interventions for a variety of 
human diseases. 
References 
1 Felbmer, P. L. (1990) Adv. Drug Deliv. Rev. 5, 163-187 
2 Graham, F. L. and van der Eb, A.J. (1973) Virology 52, 456-467 
3 Vaheri, A. and Pagano,J. S. 0965) Virology 27,434 436 
4 Minston, A. C., Wildy, P., Buchan, A. and Darby, G. (1978) Cell 13, 
481-487 
5 Lee, F., Mulligan, P,., Berg, P. and Ringold, G. (1981) Nature 294, 
228 232 
6 Fraley, P-.., Subramani, S., Berg, P. and Papahadjopoulos, D. (1980) 
215 
taNetin 2 specific diseases 
.J. Biol. Chem. 255, 10431-10435 
7 Loyter, A., Vainstein, A., Graessmann, M. and Graessmann, A. (1983) 
Exp. Cell Res. 143,415-425 
8 Felgner, P. L., Gadek, T. 1%., Holm, M., Roman, 1%., Chan, H. W., 
Wenz, M., Northrop,J. P., Ringold, G. M. and Danielsen, M. (1987) 
Proc. Natl Acad. &i. USA 84, 7413~417 
9 Feigner, P. L. and Ringold, G. M. (i989) Nature 337, 387-388 
10 Wu, C. H., Wilson,J. M. and Wu, G. Y. (1987)J. Biol. Chem. 264, 
16985-16987 
11 Cotten, M., Wagner, E., Zatloukal, K., Phillips, S., Curiel, D. T. and 
Birnstiel, M. L. (1992) Proc. Natl Acad. Sci. USA 89, 6094-6098 
12 Andersen, F. W. (1984) Science 226, 401 409 
13 Friedman, T. (1989) &ience 244, 1275 1281 
14 Felgner, P. L. and Rhodes, G. H. (1991) Nature 349, 351-352 
15 Wolff, J. A., Malone, 1K. W., Williams, P., Chong, W., Acsadi, G., 
Jani, G. and Felgner, P. L. (1990) &ience 247, 1465-1468 
16 Leinwand, L. A. and Leiden, J. M. (1991) Trends Cardiovasc. Med. 1, 
271-276 
17 Johnston, S. A. (1990) Nature 346, 776-777 
18 Hazinski, T. A., Ladd, P. A. and DeMatteo, C. A. (1991) Am.J .  
Respir. Cell Biol. 4, 206-209 
19 Yoshimura, K., Rosenfeld, M. A., Nakamura, H., Scherer, E. M., 
Pavirani, A., Lecocq, J-P. and Crystal, 1%. G. (1992) Nucleic Acids Res. 
20, 3233-3240 
20 Stribling, 1%., Brunette, E., Liggitt, D., Gaensler, K. and Debs, 1%. 
(1992) Proe. Natl Acad. Sci. USA 89, 11277-11281 
21 Nabel, E. G., Plautz, G. and Nabe], G. J. (1990) &ience 249, 
1285-1288 
22 Nabel, E. G., Plautz, G., Boyce, F. M., Stanley, J. C. and Nabel, 
G.J. (1989) Sdence 244, 1342 1344 
23 Plautz, G., Nabel, E. G. and Nabel, G. J. (1991) Circulation 83, 
578-583 
24 NabeI, E. G., Plautz, G. and Nabel, G.J. (1992) Proc. NattAcad. Sci. 
USA 89, 5157-5161 
25 Lynch, C. M., Clowes, M. M., Osborne, W. 1%. A., Clowes, A. W. 
and Miller, A. D. (1992) Proc. NatlAcad. Sa.USA 89, 1138 1142 
26 Leclerc, G., Gal, D., Takeshita, S., Nikol, S., Weir, L. and lsner, 
J. M. (1992)J. C/in. Invest. 90, 936-944 
27 Elm, C. S., Chapman, G. D., Gammon, i%. S., Muhlestein, J. B., 
Bauman, 1%. P., Stack, 1%. S. and Swain, J. L. (1991) Circulation 
83, 2007-2011 
28 Plautz, G. E., Yang, Z., Wu, B., Gao, X., Huang, L. and Nabel, 
G.J. (1993) Proc. NatIAcad. Sd. USA 90, 4645 4649 
29 Nabel, G.J. (1992) Hum.Gene Ther. 3, 705-711 
30 Gao, X. and Huang, L. (1991) Biochem. Biophys. Res. Commurl. 179, 
280-285 
31 Stewart, M. J., Plautz, G. E., Del Buono, L., Yang, Z. Y., Xu, L., 
Gao, X., Hnang, L., Nabel, E. G. and Nabel, G.J. (1992) Hum. Gene 
Ther. 3, 267-275 
32 Nabel, G.J. (1992) Hum.Gene Tiler. 3, 399-410 
33 Germain, 1%. N. (1991) Nature 353, 605 
34 1%hodes, G. H., Abai, A. M., Dwarki, V.J., Parker, S. E., Manthorpe, 
M., Feigner, J., Felgner, P. L. and Gromkowski, S. H. Vaccines (in 
press) 
35 Liu, M. A., Idlmer, J. B., Friedman, A., Martinez, D., Hawe, L. A., 
DeWitt, C. M., Leander, K. 1%., 8hi, X-P., Montgomery, D. L., Don- 
nelly, J. J., Parker, S., Felgner, P. L. and Felgner, J. Vaccines (in press) 
36 Ulmer, J. B., Donnelly, J. j., Parker, S. E., Rhodes, G. H., Feigner, 
P. L., Dwarki, V. J., Gromkowski, S. H., Deck, 1%. 1%., DeWitt, 
C. M., Friedman, A., Hawe, L. A., Leander, K. 1%., Marinez, D., 
Perry, H. C., Shiver, J. W., Montgomery, D. L. and Liu, M. A. 
(1993) Sdence 259, 1745 1749 
TIBTECH Editorial Policy 
Trends in Biotechnologyis  a news, reviews and commentary journal designed to keep its international 
readership up-to-date with the current developments in biotechnology. T I B T E C H  occupies a niche 
between primary research journals and conventional review journals - it is not a vehicle for the 
publication of original research data or methods. 
There is a strong emphasis on an integrated approach to communicating significant new advances 
in biotechnology, and discussing their commercial potential. This necessitates combining essential 
to strict standards to ensure clarity, scientific accuracy and readability. Commissioning does not 
guarantee publication. 
Reviews: Balanced and concise presentations of specific areas of research. The scope of such 
rev ews is more I m ted than those of conventional review journals, but provides surf cient nformation 
to place the latest developments in a particular field in perspective. 
Letters to the Editor. 
r reported 
_ . ~orts, and 
Biotopics: A column providing a ighter, more personal treatment of topics ranging from serious 
science and novel techniques, to finance and eth cal questions. 
Features: Review-length articles which discuss business issues relevant to all biotechnologists - 
patent ng, commercial opportunities and regulatory aspects. 
TIBTECH MAY 1993 (VOL ] 1) 
